Sutro Biopharma, Inc. / Fundamentals
Income statement
- Net revenue
€89.64M - Cost of goods sold
€1.63M - Gross profit
€86.40M - SG&A expenses
€40.31M - R&D expenses
€191.39M - EBITDA
-€141.89M - D&A
€6.41M - EBIT
-€175.92M - Interest expenses
€31.65M - EBT
-€177.06M - Tax expenses
€2.01M - Net income
-€179.06M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€10.03M - Changes in working capital
-€70.86M - Operating cash flow
-€213.52M - Capex
€2.71M - Other investing cash flow
€63.53M - Net investing cash flow
€189.70M - Total cash dividends paid
€0.00 - Issuance of common stock
-€22.33M - Debt repayment
€0.00 - Other financing cash flow
€857.14K - Net financing cash flow
€857.14K - Foreign exchange effects
€0.00 - Net change in cash
-€22.23M - Cash at end of period
€55.67M - Free cash flow
-€210.82M
Balance sheet
- Cash and cash equivalents
€54.93M - Cash and short-term investments
€176.00M - Total receivables
€6.86M - Inventory
€0.00 - Other current assets
€15.87M - Total current assets
€198.74M - Property, plant & equipment
€25.58M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€736.16K - Other non-current assets
€42.90K - Total non-current assets
€26.36M - Total assets
€225.10M - Accounts payable
€3.70M - Short-term debt
€6.91M - Other current liabilities
€42.83M - Total current liabilities
€63.70M - Long-term debt
€19.80M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€179.05M - Total non-current liabilities
€188.95M - Total liabilities
€252.65M - Common stock
€72.93K - Retained earnings
-€750.18M - Other equity
-€11.15K - Total equity
-€27.55M - Total liabilities and shareholders' equity
€225.10M
Company information
- Market capitalization
€52.88M - Employees
269 - Enterprise Value
-€15.00M
Company ratios
- Gross margin
-
96.4% Much better than peer group: -309.0% - EBITDA margin
-
-158.3% Much better than peer group: -12,835.7% - EBIT margin
-
-196.3% Much better than peer group: -12,618.5% - EBT margin
-
-197.5% Much better than peer group: -6,719.0% - Net margin
-
-199.8% Much better than peer group: -7,729.8% - ROE
-
649.9% Much better than peer group: -14.8% - ROA
-
-79.5% Much worse than peer group: -40.5% - Asset turnover
-
39.8% Much better than peer group: 3.2% - FCF margin
-
-241.2% Much better than peer group: -6,945.9% - FCF yield
-408.9% - Efficiency ratio
258.3% - Net sales per employee
-
€333.23K - Net income per employee
-
-€665.66K